Robbins P B, Skelton D C, Yu X J, Halene S, Leonard E H, Kohn D B
Department of Molecular Microbiology and Immunology, Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, University of Southern California School of Medicine, Los Angeles, CA 90027, USA.
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10182-7. doi: 10.1073/pnas.95.17.10182.
Retroviral vectors based on the Moloney murine leukemia virus (MoMuLV) have shown inconsistent levels and duration of expression as well as a propensity for the acquisition of de novo methylation in vivo. MoMuLV-based vectors are known to contain sequences that are capable of suppressing or preventing expression from the long terminal repeat. Previously, we constructed a series of modified retroviral vectors and showed that they function significantly better than MoMuLV-based vectors in vitro. To test the efficacy of the modified vectors in hematopoietic stem cells in vivo, we examined gene expression and proviral methylation in differentiated hematopoietic colonies formed in the spleens of mice after serial transplantation with transduced bone marrow (2 degreesCFU-S). We found a significant increase in the frequency of expression with our modified vectors (>90% expression in vector DNA containing 2 degreesCFU-S) over the frequency observed with the standard MoMuLV-based vector (28% expression in vector containing 2 degreesCFU-S). Expression from the modified vectors was highly consistent, with expression in >50% of the vector-containing 2 degreesCFU-S from all 20 transplant recipients analyzed, whereas expression from the standard MoMuLV-based vector was inconsistent, with expression in 0-10% of the vector containing 2 degreesCFU-S from 8 recipients and expression in >50% of the vector-containing 2 degreesCFU-S from 4 other recipients. In addition, we established that the modified vectors had a lower level of DNA methylation than the control vector. These findings represent significant advances in the development and evaluation of effective retroviral vectors for application in vivo.
基于莫洛尼鼠白血病病毒(MoMuLV)的逆转录病毒载体在体内的表达水平和持续时间不一致,且有获得从头甲基化的倾向。已知基于MoMuLV的载体含有能够抑制或阻止从长末端重复序列表达的序列。此前,我们构建了一系列修饰的逆转录病毒载体,并表明它们在体外的功能明显优于基于MoMuLV的载体。为了测试修饰载体在体内造血干细胞中的功效,我们在将转导的骨髓进行系列移植后,检查了小鼠脾脏中形成的分化造血集落中的基因表达和前病毒甲基化(二级脾集落形成单位,2°CFU-S)。我们发现,与标准的基于MoMuLV的载体相比,我们的修饰载体的表达频率显著增加(在含有2°CFU-S的载体DNA中>90%表达)(在含有2°CFU-S的载体中28%表达)。修饰载体的表达高度一致,在分析的所有20名移植受者中,>50%含有2°CFU-S的载体中有表达,而标准的基于MoMuLV的载体的表达不一致,在8名受者中,含有2°CFU-S的载体中有0-10%表达,在另外4名受者中,>50%含有2°CFU-S的载体中有表达。此外,我们确定修饰载体的DNA甲基化水平低于对照载体。这些发现代表了在开发和评估用于体内应用的有效逆转录病毒载体方面的重大进展。